Clinical trial
ALF-ONE: ALFuzosin ONcE Daily
NCT00280605 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00280605 |
|---|---|
| Title | ALF-ONE : ALFuzosin ONcE Daily |
| Official title | Study of the Outcome of Patients With Lower Urinary Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Alfuzosin 10 mg Once Daily for 3 Months in China |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Prostatic Hyperplasia |
| Intervention type | Drug |
| Interventions | Alfuzosin |
| Enrollment | 200 |
| Start date | Aug 1, 2005 |
| Primary completion | Feb 1, 2006 |
| Completion | Feb 1, 2006 |
| First posted | Jan 23, 2006 |
| Last update posted | Aug 31, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: